Xiaochan Chen

Featured in: Favicon

biomedcentral.com Favicon

arthritis-research.biomedcentral.com

Articles

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

Jan 6, 2025 | lupus.bmj.com | Yiting Chen |Xin Lei |Jianhang Xu |Xiaochan Chen

The increase of B-cell-activating factor after B-cell clearance is an important factor affecting the efficacy of rituximab (RTX) in the treatment of lupus nephritis. This study compared the efficacy and safety of RTX, followed by belimumab and telitacicept in the treatment of refractory lupus nephritis.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →